You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis
  1. Marinos C Dalakas1,2
  1. 1Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
  2. 2Neuroimmunology Unit, University of Athens Medical School, Athens, Greece
  1. Correspondence to Professor Marinos C Dalakas, Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA; mdalakas{at}med.uoa.gr

https://doi.org/10.1136/jnnp-2016-313418

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Watanabe et al1 report on prospectively studied patients with necrotising autoimmune myopathy (NAM), diagnosed among 460 individuals with inflammatory myopathies (IM), over a 4-year period. This is the largest ever NAM cohort diagnosed with histological criteria and exclusion of genetically-defined muscular dystrophies. Among 387 patients (after excluding 16% with IBM), 30% had NAM with antibodies either against SRP (18%) or HMGCR (12%); another 13% had overlap myositis (OM), also a necrotising but perifascicular myositis, with anti-Jo-1 antibodies. Considering that antibodies are presently detected in 60–80% of NAM cases,2 this carefully studied population suggests that NAM is probably one of the commonest IM accounting, along with OM, for >50% of …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles